Navigation Links
FDA asks the doctors to take the patients’ dietary history before prescribing medication,

FDA had issued a guideline called Pharmacogenomic Data Submissions for practicing physicians to check the //patients from suffering adverse effects of cocktails of drugs and diet.

Pharmacogenomics is the procedure adopted by physicians to find out the patient’s profile of response to drugs and decide on the unique treatment option best suited to the patient’s requirement. These are basically a set of tests developed to identify for example, which form of cancer responds to a certain kind of medication.

The result of such procedures will be personalizing the treatments through multiple attempts that will result in doctors identifying the patient’s genetic patterns and prescribe drugs that will give the best-suited results for the patients.

As a part of this intervention, FDA has approved the first laboratory test called the Amplichip Cytochrome P450 Genotyping Test. This will provide the medical practitioners with the patients’ genetic information which will go a long way in helping the physicians in deciding the right medication and dosage for diseases like cardiac diseases, psychiatric illnesses, and cance.
'"/>




Page: 1

Related medicine news :

1. Two doctors suspended for wrong brain surgery
2. Lure of the home turf brings back NRI doctors
3. Thakur warns doctors
4. Negligent doctors asked to cough up 3 lakhs for death of patient
5. Spreading knowledge to doctors about herbal medicine
6. Nurses competing with junior doctors in some assessments
7. Baltimore doctors perform three simultaneous kidney transplants
8. Five patients die amid Bihar doctors strike
9. Fresh warnings to doctors regarding abortion pill
10. Indian doctors in America help Katrina victims
11. Time magazine has recognized efforts of two Indian doctors towards reducing infant mortality rate

Post Your Comments:
(Date:11/27/2009)...alth™ announced today that Spectrum Health (... Enterprise orthopedic templating solution and its... (PRWEB) November 27, 2009 -- Voyant ... (Grand Rapids, Michigan) has licensed its TraumaC...ts TraumaCad Extend workflow solution, to allow it...
(Date:11/26/2009)...-Withcoldandfluseasonuponus,it,smoreimportantthane...ionsandavoidillness. ,, "Weneedtobeproactivenot...llnessifwe,resick,"saidEileenFinerty,RN,MS,CIC(cer...tioncontrolandoccupationalhealthatHospitalforSpeci...lSurgeryhasoneofthelowestinfectionratesofanyhospit...
(Date:11/26/2009)... can lead to strains or worse , , THURSD...ng wrong with stuffing your turkey full to burstin...h your suitcase as you pack for holiday trips. ,...U.S. hospital emergency rooms, doctors, offices, c...lated injuries, such as muscle strains, pulls and ...
(Date:11/26/2009)...Triangle Dental (RTDental), a leading dental group...ed the expansion of its services to include LUMINE...illan. , Durham, NC (P...nounce that Dr. Doug Macmillan, an experienced LU... advanced training seminar. RTDental’s abil...
(Date:11/25/2009)...swire/--TheBartleHallConventionCenterwilltemporari...whenKansasCityhoststhelatestinaseriesofmassivefree...enthasthepotentialtobethebiggestoneyet,becauseitwi...daysinsteadofoveraweekend,"SheriWood,executivedire...heNationalAssociationofFreeClinics(NAFC). ,, At...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2
... addresses health disparities in children; adolesc...tion for Quality Healthcare announced today that i...ity Health Centers, Inc. (MCCHC) in Alexandria, I... children. , , The program focuses on conducting ...
...r Human Rights responds to the publication of a l...e Red Cross which concludes that health profession...et detention centers committed gross violations of... confidential International Committee of the Red C...
... ETS EXPOSURE , Environmental tobacco smoke (ETS) ...n children. However, a new study shows that reduci...iversity of Alabama researchers followed 240 child...ded to caregivers; however, children were given 20...
... of African American employees , , GAITHERSBURG,...xo, a leading integrated food and facilities manag...t who I am as an African American and a woman and ... African American Leadership Forum network group. ...
...he comScore, Inc. February rankings, Health Guru M... growing health site on the web over the last thre...o one of the few health sites with more video view...ruary rankings, Health Guru Media (HealthGuru.com)...
...lp facilitate dialogue,during an eye examination b...Hispanic patients, Transitions Optical has develop...his free bilingual guide illustrates key steps tha...n,critical to making the best possible recommendat...
Other Medicine News:Health News:Centene Foundation for Quality Healthcare Awards Grant to Community Health Center 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 2Health News:In Wake of ICRC Report, Health Professionals Must Be Held Accountable for Torture 3Health News:Journal Chest: April news briefs 2Health News:Sodexo Named as One of the Top Three Companies for African Americans on 2009 DiversityInc Top Ten Companies List 2Health News:Web's Fastest Growing Health Site is a Video Site 2Health News:Web's Fastest Growing Health Site is a Video Site 3Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 2Health News:Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals 3
(Date:11/25/2009)...stCall/--ERT(Nasdaq: ERES ),announcedtodaythatDr.M...ithSchneck,theCompany,sExecutiveVicePresidentandCF...HealthCareConferenceat1:30PMESTonDecember1,2009inN...ssthepresentationbyvisitingtheCompany,scorporatewe...essedat http://www.corporate-ir.net/ireye/conflobb...
(Date:11/25/2009)...USNewswire/--RemediumTechnologiesInc.,acompanydeve...g,wonfirstprizeand$10,000intheMostPromisingSecurit...anyofficialsannouncetoday. ,, Selectedfrommoret...hedtheirinventionattheGSCSecuritySummitconferenceh...w.remediumtechnologies.com )isdevelopingahigh-pres...
(Date:11/25/2009)...linker.comannouncesthatanewmarketresearchreportisa...nt-AGlobalMarketPerspective ,, http://www.re...Global-Market-Perspective.html ,, Risingincide...gnationsisaprincipalfactorinfluencinggrowthinthema...reastcancerhasallowedwomentocomeforwardfortheiryea...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 1Extending treatment after liver transplant may benefit patients with hepatitis C recurrence 60452 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 1Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 2Toronto Conference Targets the Vitamin D Deficiency Crisis 60448 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 1BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 2BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 3BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 4BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 5BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 6BYETTA Approved for Expanded Use as First Line Treatment for Type 2 Diabetes 14673 7
...tro Assays Show rBChE Suppresses Amyloid Plaque,Fo...ene, Inc., a leading,biodefense company specializi...ical countermeasures against chemical and,biologic...ts,recombinant butyrylcholinesterase (rBChE) resea...ernational Conference on,Alzheimer,s and Parkinson...
...T, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- ...perative Oncology Group,(ECOG) has reported that i...liminary results from a large, randomized clinical...myeloma has found,that the use of a low dose of de...omide suggests survival advantage for,patients whe...
Other Medicine Technology:Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5Pharmathene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 2ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 3ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 4ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 5ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 6ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03),Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival,Advantage for Patients with Multiple Myeloma 7
... access wire into the renal pelvis through a 21 ga...andril type shaft construction provides rigidity w...) diameter wire guide. The distal portion of the w...tapered mandril which provides tip flexibility. Su...
Two-Part Trocar Needles - Standard
Skinny Needle® (With Chiba Tip) - Standard
Fiberoptic Light Guide with Fixed ACMI™ Light Source End
Medicine Products: